←back to Blog

Elarekibep, an inhaled Anticalin protein, targets IL-4Ralpha locally: first-in-human randomized phase 1 trials of a novel potential therapeutic class in asthma

Respir Res. 2026 Aug 19;27(1):441. doi: 10.1186/s12931-026-03854-5.

ABSTRACT

BACKGROUND: Elarekibep (AZD1402/PRS-060) is an Anticalin, a new class of inhaled therapeutic proteins, which has been engineered to inhibit interleukin-4 receptor α-subunit (IL-4Rα) signalling, a key target in asthma.

METHODS: Two phase 1 randomized, first-in-human, dose-escalating, single-blind studies (NCT03384290; NCT03574805) investigated single ascending doses (SADs) or multiple ascending doses (MADs) of elarekibep compared with placebo. In the SAD study, healthy participants received a single inhaled dose of elarekibep 0.1-160 mg, intravenous doses of 1 mg or 2 mg, or matched placebo. In the MAD study, participants with mild asthma and elevated fractional exhaled nitric oxide (FeNO) received inhaled doses of elarekibep 0.2-60 mg or placebo twice daily for 10 or 17 days (single dose on day 10 in all but one cohort), continuously or intermittently.

RESULTS: In total, 148 participants were enrolled across both studies. No safety concerns were reported. Treatment-emergent adverse events were experienced by 34.7% (elarekibep, 35.2%; placebo, 33.3%) and 81.6% (elarekibep, 75.9%; placebo, 95.5%) of SAD and MAD study participants, respectively. Elarekibep was absorbed after inhalation, with dose-related increases in systemic exposure detectable with doses greater than or equal to 6 mg. In both studies, systemic exposure resulted in decreased levels of phosphorylated signal transducer and activator of transcription 6, a biomarker for systemic IL-4Rα target engagement. In the MAD study, rapid reductions of FeNO were demonstrated with doses greater than or equal to 2 mg, indicating pulmonary target engagement.

CONCLUSIONS: Elarekibep was well tolerated in both studies and demonstrated pulmonary and systemic target engagement. Elarekibep was investigated further in a phase 2a study (NCT04643158).

TRIAL REGISTRATION: NCT03384290. Registered 26 November 2017, https://clinicaltrials.gov/ct2/show/NCT03384290 . NCT03574805. Registered 2 July 2018, https://clinicaltrials.gov/ct2/show/NCT03574805 .

PMID:43035707 | DOI:10.1186/s12931-026-03854-5